Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zero Candida TechnologiesTSXV:ZCT 14 5-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates TSXV:ZCT with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 702 Medical Devices & Instruments companies, Zero Candida Technologies ranks worse than 142450% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Zero Candida Technologies does not have enough data to calculate 5-Year RORE %.
Zero Candida Technologies (TSXV:ZCT) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Zero Candida Technologies 5-Year RORE % Related Terms
Zero Candida Technologies 5-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:ZCT vs ABT, SYK, MDT: 5-Year RORE % Comparison
For the Medical Devices subindustry, Zero Candida Technologies's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zero Candida Technologies 5-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zero Candida Technologies's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Zero Candida Technologies's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 5-year before.
Zero Candida Technologies (TSXV:ZCT) has a 5-Year RORE % of 0.00 as of Dec. 2025. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Zero Candida Technologies and its competitors. According to the industry distribution chart, Zero Candida Technologies ranks #999999 out of 702 companies in the Medical Devices & Instruments industry.
Is Zero Candida Technologies' 5-Year RORE % too high?
Zero Candida Technologies' current 5-Year RORE % is 0.00. Based on the distribution chart, Zero Candida Technologies ranks #999999 out of 702 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Zero Candida Technologies has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Zero Candida Technologies' 5-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zero Candida Technologies ranks #999999 out of 702 companies for 5-Year RORE %. This places Zero Candida Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Zero Candida Technologies and its competitors. Zero Candida Technologies's current 5-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zero Candida Technologies stock overvalued right now?
Zero Candida Technologies (TSXV:ZCT) has a current 5-Year RORE % of 0.00. The current 5-Year RORE % is 0.00. Zero Candida Technologies' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Zero Candida Technologies (TSXV:ZCT), the current 5-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zero Candida Technologies Inc is engaged in providing female healthcare solutions. The company technology uses a controlled Blue Light to destroy the fungus at record speed and without side effects. It focused on developing and commercializing several patents and patent applications concerning an AI smart tampon-like device, designed to treat Candidiasis and transfer medical information via Wi-Fi to the doctor.
14GF Score
Get the complete analysis for TSXV:ZCT
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZCT has been successfully added to your 
